Kriya Therapeutics – a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world – recently announced the addition of over $150 million in capital committed as part of its Series C Financing, bringing the total Series C round to over $430 million. The proceeds from the funding will support the clinical translation of Kriya’s broad pipeline of gene therapies and the continued scaling of its engineering, computational and manufacturing platforms.
Since being founded in October 2019, Kriya raised over $600 million in committed capital. And with this funding round, Kriya’s cash runway is anticipated to run into late 2026.
The company is developing a portfolio of transformational gene therapies focused on three main therapeutic areas: ophthalmology, neurology, and metabolic disease. Within each therapeutic area, the company has strategically focused on addressing prevalent diseases with significant unmet medical needs, validated biological targets, and well-defined clinical endpoints so that it may rapidly achieve proof-of-concept through accelerated translational development.
KEY QUOTES:
“We have an ambitious goal to advance gene therapies to highly prevalent diseases that affect millions of people around the world. In order to make gene therapies a cornerstone of mainstream medicine, we have built a fully integrated engine to overcome industry-wide challenges that have constrained research, development and manufacturing in the field of gene therapy. Our investments in world class infrastructure and talent have supported our ability to move with unprecedented efficiency in the engineering and production of gene therapies—and we look forward to the next chapter of our company’s evolution as we translate our programs into the clinic where they can hopefully help patients in desperate need of better treatment options.”
— Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya
“We are excited about the promise that gene therapy holds for the field, including its potential to usher in a new era of medicine—a future where gene therapy is not confined to a limited range of rare diseases but instead harnessed to address a wide array of medical conditions. Importantly, we believe in the approach that Kriya is taking to lead the way into this exciting future.”
— Jim Momtazee, Managing Partner of Patient Square Capital – who led the Series C financing
